Imagin Medical announces $600K private placement

News Release

IMAGIN MEDICAL ANNOUNCES PRIVATE PLACEMENT

Vancouver, B.C. and Boston, MA, September 26, 2017 – Imagin Medical, Inc. (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today the offering of a non-brokered private placement to raise $600,000 through the distribution of units (“Units”) at $0.05 per Unit.

Each Unit will consist of one common share and one common share purchase warrant, each warrant entitling the holder to acquire one additional common share at $0.10 for 12 months.

Finder’s fees may be paid in accordance with Canadian Securities Exchange policies. Closing of the placement will be subject to making applicable filings with the CSE.

Proceeds from the placement will be used for general working capital purposes, including advancing the development of imaging solutions for the early detection of cancer.

Pursuant to the Company’s Stock Option Plan, an aggregate of 1.6M shares have been granted to consultants as incentive stock options at an exercise price of $0.06 per share. The options are exercisable for a period of five years, ending on September 25, 2022.

About Imagin Medical

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com

For further information, contact:
Jim Hutchens, President & CEO
Telephone: (617) 571-6006
Email: jhutchens@imaginmedical.com